FMS Stock News & Catalysts

FEATURED

Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook

Stable organic revenue1 development driven by growth in Care Delivery and Care Enablement, offset by the expected decline in profit-neutral Value-Based CareOperating income2 decreased by 6%, due to regulatory and

Summary

Nov 3, 2026, 7:00 AM ·PRNewswire

RECENT

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous

Oct 21, 2026, 6:10 PM ·PRNewswire

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

New U.S. real-world evidence demonstrates high-volume hemodiafiltration (HvHDF) can be successfully delivered in routine clinical practice, with treatment targets comparable to those reported in EuropeGLP-1 receptor

Oct 19, 2026, 9:00 AM ·PRNewswire

Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

BAD HOMBURG, Germany, Oct. 7, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced that Shervin J. Korangy

Oct 7, 2026, 11:28 AM ·PRNewswire

Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

Refinements support the Company's China go-to-market and commercial strategy in an important and growing marketStrategy focuses on localized portfolio and innovation in ChinaPortfolio decisions expected to result in

Sep 25, 2026, 8:00 AM ·PRNewswire

Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis

Publication in the Journal of the American Society of Nephrology reports that, in a large multinational real-world evidence study using a target trial emulation design, hemodiafiltration (HDF) was associated with a 28%

Aug 27, 2026, 9:00 AM ·PRNewswire

Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery

BAD HOMBURG, Germany, Aug. 3, 2026 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, has appointed Cassie

Aug 3, 2026, 2:20 PM ·PRNewswire

Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda

Organic revenue growth1 of 5% with growth in all operating segmentsOperating income2 grew by 23%, resulting in further margin expansion to 11.7%Reported operating income grew by 10% and reported net income3 decreased by

Aug 3, 2026, 2:20 PM ·PRNewswire

Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients

BEACON-US research initiative is evaluating the clinical outcomes and patient experiences of high-volume hemodiafiltration in routine U.S. clinical practice across diverse patient populationsFresenius Medical Care

Jul 29, 2026, 9:00 AM ·PRNewswire

Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy

Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settingsAvailable within NxStage® System One™ with NxView™ 4.0, Fresenius

Jul 20, 2026, 8:00 AM ·PRNewswire

Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis

Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programsDesigned to simplify care processes for healthcare teams and their patients

Jun 3, 2026, 8:00 AM ·PRNewswire

Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million

BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch of the first

May 28, 2026, 7:00 AM ·PRNewswire

Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026

Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalizationNew research focuses on applying real-world evidence,

May 27, 2026, 9:05 AM ·PRNewswire

Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months

Total volume of the share buyback is around EUR 1 billion over 12 monthsShare buyback expected to begin in the near futureBAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's

May 26, 2026, 7:00 AM ·PRNewswire

Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care

Shareholders approve proposed dividend of EUR 1.49 per shareFME Reignite strategy launched in 2025 successfully drives the next phase of value creation5008X CAREsystem introduced in U.S. clinics; full U.S. commercial

May 21, 2026, 10:13 AM ·PRNewswire

Fresenius Medical Care AG & Co. KGaA FMS · News